Literature DB >> 1708934

Two immunodominant regions of the human papillomavirus type 16 E7 protein are masked in the nuclei of monkey COS-1 cells.

T Kanda1, S Zanma, S Watanabe, A Furuno, K Yoshiike.   

Abstract

The human papillomavirus type 16 E7 protein is a 98-amino acid (AA)-long nuclear oncoprotein. We established eight independent mouse hybridoma cell lines producing monoclonal antibodies (MAbs) specific for the E7 protein and characterized the MAbs by competitive binding analysis with the bacterially expressed, nonfusion E7 protein and synthesized oligopeptides. The MAbs were classified into two groups; three and five MAbs recognizing epitopes in probable immunodominant regions AAs 8 to 22 (region I) and AAs 39 to 54 (region II), respectively. These MAbs were capable of immunoprecipitating the E7 protein transiently expressed in monkey COS-1 cells. By immunofluorescence staining of the acetone-fixed E7-producing COS-1 cells, the MAbs for regions I and II detected no E7 protein and only cytoplasmic E7 protein, respectively, whereas a rabbit polyclonal antiserum (anti-lac-E7) detects both nuclear and cytoplasmic E7 proteins. Like anti-lac-E7, the MAbs of the two groups stained both nuclear and cytoplasmic E7 proteins in the COS-1 cells that were denatured with formaldehyde. The results show that two immunodominant regions of the HPV 16 E7 protein are masked in the COS-1 nuclei for binding with the corresponding MAbs. The masking of the intranuclear E7 protein may result from complex formation with cellular proteins (or structures), polymerization, or self-folding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708934     DOI: 10.1016/0042-6822(91)90613-g

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Human papillomavirus 16 E7 protein is associated with the nuclear matrix.

Authors:  I Greenfield; J Nickerson; S Penman; M Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Feline immunodeficiency virus Vif localizes to the nucleus.

Authors:  U Chatterji; C K Grant; J H Elder
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.

Authors:  Angel Cid-Arregui; Victoria Juárez; Harald zur Hausen
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein.

Authors:  W Zwerschke; S Mazurek; P Massimi; L Banks; E Eigenbrodt; P Jansen-Dürr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

6.  Detection of human antibody against the human papillomavirus type 16 E7 protein.

Authors:  M Hashido; T Kanda; S Zanma; S Watanabe; N Komiyama; H Yoshikawa; N Yamaguchi; T Kawana; K Yoshiike
Journal:  Jpn J Cancer Res       Date:  1991-12

7.  Enhancer-promoter activity of human papillomavirus type 16 long control regions isolated from cell lines SiHa and CaSki and cervical cancer biopsies.

Authors:  T Kozuka; Y Aoki; K Nakagawa; K Ohtomo; H Yoshikawa; K Matsumoto; K Yoshiike; T Kanda
Journal:  Jpn J Cancer Res       Date:  2000-03

8.  Different Isoforms of HPV-16 E7 Protein are Present in Cytoplasm and Nucleus.

Authors:  H Valdovinos-Torres; M Orozco-Morales; A Pedroza-Saavedra; L Padilla-Noriega; F Esquivel-Guadarrama; L Gutierrez-Xicotencatl
Journal:  Open Virol J       Date:  2008-03-26

9.  Growth dependence of human papillomavirus 16 DNA-positive cervical cancer cell lines and human papillomavirus 16-transformed human and rat cells on the viral oncoproteins.

Authors:  S Watanabe; T Kanda; K Yoshiike
Journal:  Jpn J Cancer Res       Date:  1993-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.